BioCentury
ARTICLE | Company News

Celgene exercises option to acquire Quanticel

April 28, 2015 1:23 AM UTC

Celgene Corp. (NASDAQ:CELG) exercised its option to acquire Quanticel Pharmaceuticals Inc. (San Francisco, Calif.) for $100 million up front. Celgene gains Quanticel's platform to perform single-cell genomic analysis of tumors along with preclinical oncology candidates that target undisclosed epigenetic modifiers.

Celgene received the option to acquire Quanticel under a 2011 deal that also gave it an undisclosed equity stake. Quanticel's shareholders, including founding investor Versant Ventures, are eligible for $385 million in R&D and regulatory milestones (see BioCentury, Nov. 14, 2011). ...